Academic Journal
Q1Alzheimer’s Research and Therapy
About Alzheimer’s Research and Therapy
Alzheimer's Research and Therapy is a scholarly journal published by BioMed Central Ltd. SCImago 2025 lists it in Q1, with an SJR of 2.479 and H-index of 123.
Coverage: 2010-2026. Research categories: Cognitive Neuroscience (Q1); Neurology (Q1); Neurology (clinical) (Q1).
Verified field sources
- Journal Impact Factor: 8.9 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Impact Factor year: 2025 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Editor(s): Delphine Boche PhD; Kristian Steen Frederiksen MD, PhD; Charlotte Teunissen PhD (Editors-in-Chief) — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-03-17. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Dementia and Cognitive Impairment Research; Alzheimer's disease research and treatments; Functional Brain Connectivity Studies; Neuroinflammation and Neurodegeneration Mechanisms; Intracerebral and Subarachnoid Hemorrhage Research; Neurological Disease Mechanisms and Treatments.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
TNFR2 agonist treatment differentially affects neuropathology and neuroimmune responses in male and female 3xTg-AD mice
Irem Bayraktaroglu, Melanie Eschborn, Ilse Zwiers, Kylan van Vliet et al.
2026-10-03 · DOI: 10.1186/s13195-026-02217-yMulti-omic characterization of CR1+ oligodendrocytes reveals conserved pathology and a peripheral biomarker in Alzheimer’s disease
Shuangjie Qian, Hao Zhu, Leran Hu, Kathy Fu et al.
2026-10-02 · DOI: 10.1186/s13195-026-02201-6Education, cognitive reserve and brain pathology in aging and Alzheimer’s disease: evidence from preclinical and symptomatic cohorts
Shima Raeesi, Amelie Metz, Katherine Chadwick, Yashar Zeighami et al.
2026-10-02 · DOI: 10.1186/s13195-026-02192-4Reducing Alzheimer’s diagnostic uncertainty with a sequential plasma p-tau217 workflow in real-world memory clinic practice
Giordano Cecchetti, Federica Agosta, Giulia Rugarli, Federico Coraglia et al.
2026-10-02 · DOI: 10.1186/s13195-026-02218-xCriteria-based probable REM sleep behaviour disorder and risk of Lewy body dementia: analyses of a memory clinic cohort and a community cohort
Ji Won Han, Dae Jong Oh, Yu Jung Choi, Tae Hui Kim et al.
2026-10-02 · DOI: 10.1186/s13195-026-02207-0Correction: Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer’s disease
Noor Abdulhameed, Alice Babin, Kim Hansen, Riley Weaver et al.
2026-10-02 · DOI: 10.1186/s13195-026-02200-7Integrating genetically predicted transcriptomic signatures with longitudinal real-world data for drug repurposing in Alzheimer’s disease
Monika E. Grabowska, Rui Chen, Ying Zhou, Avi U. Vaidya et al.
2026-10-02 · DOI: 10.1186/s13195-026-02215-0Locus coeruleus activity is related to sleep and 24-h rest-activity rhythms in the context of plasma Alzheimer’s disease markers: a 7T MRI study of older individuals
Yuliya Patsyuk, Prokopis Prokopiou, Nicholas J. Ashton, Shorena Janelidze et al.
2026-10-01 · DOI: 10.1186/s13195-026-02216-zHigher HDL cholesterol is associated with greater amyloid-β oligomerization in older adults
Shin Gyeom Kim, Hyun Soo Kim, Hye Ji Choi, Young Min Choe et al.
2026-10-01 · DOI: 10.1186/s13195-026-02181-7Commercially available apps for the treatment of people living with dementia and mild cognitive impairment: a systematic review. What evidence and what urgencies from a public health perspective?
Francesco Sciancalepore, Antonio Ancidoni, Alice Paggetti, Elisa Fabrizi et al.
2026-10-01 · DOI: 10.1186/s13195-026-02206-1A centiloid-scaled crossover of amyloid and tau influences on plasma p-Tau217 along the Alzheimer’s disease continuum
Hyunwoo Lee, Yuna Gu, Heekyoung Kang, Daeun Shin et al.
2026-09-29 · DOI: 10.1186/s13195-026-02210-5Correction: The incremental predictive value of biological aging indicators for cognitive impairment in older adults: a longitudinal analysis on the Mr. OS & Ms. OS cohort
Yafei Wu, Ting Zhang, Tung Wai Auyeung, Jenny Lee et al.
2026-09-29 · DOI: 10.1186/s13195-026-02198-yImpaired peptide amidation and risk of incident dementia in the Malmoe preventive project cohort
Paul Kaufmann, Yulia Ilina, Alice Giontella, Michaela Press et al.
2026-09-28 · DOI: 10.1186/s13195-026-02173-7White matter dysfunction in Alzheimer’s disease: a convergence or divergence of hypotheses
Naiomi Rambarack, Tammaryn Lashley, Josephine Barnes, Conceição Bettencourt et al.
2026-09-26 · DOI: 10.1186/s13195-026-02208-zTest-retest reliability of plasma biomarkers and digital cognitive metrics at clinically meaningful timescales
S Toniolo, S Zhao, M Broulidakis, A Fower et al.
2026-09-26 · DOI: 10.1186/s13195-026-02205-2Correction: Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer’s disease and Parkinson’s disease
Lorenzo Gaetani, Giovanni Bellomo, Davide Chiasserini, Charlotte De Rocker et al.
2026-09-26 · DOI: 10.1186/s13195-026-02197-zCorrection: Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data
Moeko Noguchi-Shinohara, Takahiro Yoshinobu, Taro Ozaki, Daiki Muramatsu et al.
2026-09-26 · DOI: 10.1186/s13195-026-02196-0Fecal Aβ and tau aggregates are elevated in cognitive impairment and reveal peripheral proteopathic alterations
Pelin Özdüzenciler, Laura Müller, Esra Kara, Maria-Christina Weber et al.
2026-09-26 · DOI: 10.1186/s13195-026-02188-0Repetitive transcranial magnetic stimulation ameliorates cognitive dysfunction in Alzheimer’s disease by regulating microglia-neuron crosstalk via the CX3CL1-CX3CR1 axis
Xizhen Kang, Jun Tian, Qing Shu, Tingting Cheng et al.
2026-09-26 · DOI: 10.1186/s13195-026-02183-5AGS compounds as a novel therapeutic approach in a mouse model of Alzheimer’s disease
Natalie Baruch-Eliyahu, Elad Bar Gil, Vladislav Rud, Alex Braiman et al.
2026-09-25 · DOI: 10.1186/s13195-026-02193-3Reviews
Community Reviews
Version History
September 25, 2026 at 6:41 am
September 20, 2026